PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsatypical hemolytic uremic syndrome
MeSH D065766 - atypical hemolytic uremic syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D006463:Hemolytic-uremic syndrome
0 Companies
0 Drugs
Success rate
D065766: 
Atypical hemolytic uremic syndrome
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Alexion PharmaceuticalsEculizumab Soliris  2007-03-16 $4,068.9 M Q2/20-Q1/21 
Ravulizumab Ultomiris  2018-12-21 $1,200.8 M Q2/20-Q1/21 
AmgenEculizumab Bekemv  2023-04-19   
Clinical Trials
Historical Success Rate
Phase 1
0%
0/0
Phase 2
33%
1/3
Phase 3
63%
5/8
Approved: 3Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Alexion Pharmaceuticals
Amgen
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use